Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 5, 2003, Pages 781-793

  Reubi, Jean Claude ^a   Waser, Beatrice ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Neuroendocrine tumours; Peptide receptors; Somatostatin; Tumour targeting

Indexed keywords

BOMBESIN RECEPTOR; CHOLECYSTOKININ RECEPTOR; GLUCAGON LIKE PEPTIDE RECEPTOR; LIGAND; PEPTIDE; RADIOISOTOPE; RADIOLIGAND; RECEPTOR PROTEIN; RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

AUTORADIOGRAPHY; BRONCHUS CARCINOID; CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CARCINOID; DISEASE ASSOCIATION; GASTRINOMA; GENE OVEREXPRESSION; HUMAN; ILEUM CANCER; IN VITRO STUDY; INCIDENCE; INSULINOMA; INTESTINE TUMOR; ISOTOPE LABELING; LUNG TUMOR; METHODOLOGY; NEUROENDOCRINE TUMOR; NUCLEAR MEDICINE; PANCREAS TUMOR; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; RECEPTOR DENSITY; REVIEW;

EID: 0037907532     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1184-3     Document Type: Review

References (37)

1. Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooij PPM, Ausema L, Lameris JS, Reubi JC, Lamberts SWJ. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 1:242-244.
2. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998; 351:417-418.
3. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997; 57:1377-1386.
4. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999; 59:1152-1159.
5. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 1995; 36:1846-1853.
6. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Yang Q, Radosavljevic M, Leimer M, Kaserer K, Li SR, Kornek G, Hübsch P, Niederle B, Pidlich J, Scheithauer W, Valent P. 123-I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol 1996; 23:685-692.
7. Behr TM, Jenner N, Behe M, Angerstein C, Gratz S, Raue F, Becker W. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999; 40:1029-1044.
8. Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, Peers S, Thornback J, Slegers G, Dierckx RA. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000; 27:1694-1699.
9. Reubi JC, Läderach U, Waser B, Gebbers J-O, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 2000; 60:3105-3112.
10. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-Tyr(6), beta-Ala(11), Phe(13), Nle(14)] bombesin(6-14). Clin Cancer Res 2002; 8:1139-1146.
11. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28:836-846.
12. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med 1996; 125:26-34.
13. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC. Somatostatin receptor scintigraphy. New York: Raven Press, 1995.
14. 111In-pentetreotide scintigraphy. J Nucl Med 2002; 43:889-895.
15. Reubi JC, Gugger M, Waser B. Coexpressed peptide receptors in breast cancers as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med 2002; 29:855-862.
16. Wank SA. Cholecystokinin receptors. Am J Physiol 1995; 269:G628-G646.
17. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998; 50:265-270.
18. Kroog GS, Jensen RT, Battey JF. Mammalian bombesin receptors. Med Res Rev 1995; 15:389-417.
19. Hoyer D, Epelbaum J, Feniuk W, Humphrey PPA, Meyerhof W, O'Caroll AM, Patel Y, Reisine T, Reubi JC, Schindler M, Schonbrunn A, Taylor JE, Vezzani A. Somatostatin receptors. In: Girdlestrom D, ed. The IUPHAR compendium of receptor characterization and classification. London, UK: IUPHAR Media; 2000:354-364.
20. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994; 107:1848-1855.
21. Palacios JM, Dietl MM. Regulatory peptide receptors: visualization by autoradiography. Experientia 1987; 43:750-761.
22. Reubi JC, Gugger M, Waser B, Schaer JC. Y-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 2001; 61:4636-4641.
23. 0]octreotide in patients. Eur J Nucl Med 2001; 28:1319-1325.
24. Papotti M, Croce S, Macri L, Funaro A, Pecchioni C, Schindler M, Bussolati G. Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol 2000; 9:47-57.
25. Janson ET, Stridsberg M, Gobl A, Weslin J-E, Oeberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 1998; 58:2375-2378.
26. Reubi JC, Kappeler A, Waser B, Laissue JA, Hipkin RW, Schonbrunn A. Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol 1998; 153:233-245.
27. Reubi JC, Schaer JC, Waser B, Hoeger C, Rivier J. A selective analog for the somatostatin receptor subtype sst1 expressed by human tumors. Eur J Pharmacol 1998; 345:103-110.
28. Reubi JC, Eisenwiener KP, Rink H, Waser B, Macke HR. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 2002; 456:45-49.
29. Reubi JC, Waser B, Schaer JC, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab 1995; 80:2806-2814.
30. Reubi JC, Waser B, Laissue JA, Gebbers J-O. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Cancer Res 1996; 56:1922-1931.
31. 99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med 2003; 30:247-258.
32. 99mTc bombesin. A preliminary report. Tumori 2002; 88:S25-S28.
33. 123I]-Exendin4[Y39] in a rat tumor model. J Nucl Med 2000; 41 Suppl 5:9P.
34. 90Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001; 42:1841-1846.
35. Schmitt HS, Wild D, Ginj M, Reubi JC, Waser B, de Jong M, Bernard BF, Krenning EP, Mäcke HR. DOTA-NOC, a high affinity ligand of the somatostatin receptor subtypes 2, 3 and 5 for radiotherapy. J Labelled Cpd Radiopharm 2001; 44 Suppl 1:S697-S699.
36. Soll RM, Dinger MC, Lundell I, Larhammer D, Beck-Sickinger AG. Novel analogues of neuropeptide Y with a preference for the Y1-receptor. Eur J Biochem 2001; 268:2828-2837.
37. Bernard BF, Béhé M, Breeman WAP, Nock B, Maecke HR, Schmitt J, Behr TM, Maina T, Waser B, Reubi J, Krenning EP, de Jong M. Preclinical evaluation of minigastrin analogs for CCK-B receptor targeting. Cancer Biother Radiopharm 2003; in press.